Tevogen Bio (TVGN) Projected to Post Quarterly Earnings on Tuesday

Tevogen Bio (NASDAQ:TVGN) is expected to announce its results before the market opens on Tuesday, March 31st. Analysts expect the company to announce earnings of ($0.0620) per share for the quarter.

Tevogen Bio Stock Performance

NASDAQ TVGN opened at $4.36 on Friday. The firm has a market capitalization of $17.66 million, a price-to-earnings ratio of -0.46 and a beta of -0.76. Tevogen Bio has a one year low of $4.18 and a one year high of $75.50. The company’s 50 day moving average price is $11.53 and its 200 day moving average price is $21.74.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on TVGN shares. Wall Street Zen lowered shares of Tevogen Bio to a “strong sell” rating in a research report on Saturday, March 21st. Weiss Ratings restated a “sell (e+)” rating on shares of Tevogen Bio in a report on Wednesday, January 21st. Finally, D. Boral Capital downgraded Tevogen Bio from a “buy” rating to a “hold” rating in a report on Wednesday, March 4th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $100.00.

Hedge Funds Weigh In On Tevogen Bio

A number of institutional investors and hedge funds have recently bought and sold shares of TVGN. Goldman Sachs Group Inc. grew its position in Tevogen Bio by 126.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock valued at $91,000 after acquiring an additional 152,572 shares in the last quarter. Deutsche Bank AG lifted its position in shares of Tevogen Bio by 304.1% during the fourth quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock worth $57,000 after purchasing an additional 130,738 shares in the last quarter. Finally, Bridgeway Capital Management LLC boosted its stake in shares of Tevogen Bio by 66.7% in the third quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock valued at $65,000 after purchasing an additional 33,000 shares during the period.

Tevogen Bio Company Profile

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.